| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 34.89B | 31.93B |
| Cost of Revenue | 24.56B | 8.6B |
| Gross Profit | 10.32B | 23.33B |
| Operating Expenses | 24.39B | 17.23B |
| Research and Development | 72M | 100M |
| Selling, General & Administrative Expenses | 1.7B | 1.24B |
| Selling & Marketing Expenses | 203M | 185M |
| General & Administrative Expenses | 1.49B | 1.05B |
| Other Expenses | 0 | 709M |
| Operating Income | 6.47B | 6.46B |
| Total Other Income/Expenses Net | -260M | -402M |
| Income Before Tax | 6.21B | 5.94B |
| Income Tax | 1.11B | 1.29B |
| Net Income | 5.1B | 4.64B |
| Basic EPS | 12.71 | 11.59 |
| EPS Diluted | 12.69 | 11.51 |
| Basic Average Shares | 401.38M | 400.66M |
| Diluted Average Shares | 401.97M | 403.63M |
| EBITDA | 10.85B | 9.88B |
Syngene International Limited
SYNGENE.NS
NSE
701.8INR10.1 (-0.49%)
SYNGENE.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 29.73B | 25.78B |
| Net Income | 5.1B | 4.64B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | -503M | -401M |
| Retained Earnings | 34.36B | 29.73B |
| Other Distributions | 4.13B | 3.54B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 36.25B | 27.77B |
| Annual Depreciation | 4.26B | 3.6B |
| Capital Expenditure | -4.92B | -5.33B |
| Net PPE | 36.91B | 29.51B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 0 | 0 |
| Goodwill (Previous Year) | 0 | 0 |
| Goodwill | 0 | 0 |